RESEARCH PROGRAM · SCIENTIFIC CONTEXT
Keep every evidence stream in its proper lane.
Human clinical genetics, neural functional genomics, mechanistic models, and longitudinal information answer different parts of the ASH1L problem. None can silently substitute for another.
CURRENT SCIENTIFIC CONTEXT
4 evidence streams now define the next study.
Human genetics, functional genomics, mechanistic models, and longitudinal clinical data each answer a different part of the ASH1L problem.
01Human clinical genetics
Published cohorts establish a heterogeneous ASH1L-related neurodevelopmental phenotype and a primary loss-of-function mechanism. Variant class and protein position have not yet yielded a simple, validated severity ladder.
Human studies →02Human neural functional genomics
The 2026 Nature Neuroscience multi-gene CRISPR study examined ASH1L knockout across neural developmental states. ASH1L loss contributed to a mitochondrial membrane-potential signal in the pooled screen, while arrayed ASH1L knockout did not significantly change the reported Seahorse respiratory parameters. It is direct complete-gene-knockout evidence—not a heterozygous patient-allele dosage assay or a mitochondrial diagnosis.
Fernandez Garcia et al. ↗03He Lab models and active questions
Peer-reviewed He Lab mouse studies support developmental, transcriptional, sleep, metabolism, neural-activity, seizure-threshold, and preclinical-rescue questions.
Open the detailed context ↓04Clinical information over time
The available histories preserve timing, surrounding conditions, recovery, observations in adulthood and during transitions, possible trajectories, uneven documentation, and multisystem co-occurrence within the same person. They can help form research questions; prospective confirmation is still required.
Natural history framework →SCIENTIFIC DIALOGUE · HE LAB
Published models and active questions stay distinct.
He Lab studies provide developmental, transcriptional, sleep, metabolism, neural-activity, seizure-threshold, and preclinical-rescue context. Model results do not establish a human symptom mechanism, treatment indication, or individual response prediction.
Mouse circuit manipulation and human-neuron chromatin studies show that selected downstream phenotypes can be modified without establishing a pediatric therapy. The 2026 estradiol preprint similarly supports replication, dose–response, timing, safety, and mechanism studies before any human interventional interpretation.
Qin et al. ↗ · Cheon et al. ↗ · 2026 preprint ↗COLLABORATE
Bring clinical depth, mechanistic expertise, and meaningful participation together.
Investigator-led studies require appropriate ethics review, consent, secure data stewardship, and a clear plan for sharing results with participants.
Discuss a collaborationFamiliesLongitudinal history, function, record access, and research priorities.
CliniciansPhenotype validation, examination, differential interpretation, and clinical safety.
ResearchersProtocol design, assays, statistics, stewardship, and reproducibility.